Tenecteplase for Acute Ischemic Stroke: From Molecular Bioengineering to Phase III Pivotal Trials
Article information
Abstract
Intravenous thrombolysis with alteplase is a primary reperfusion therapy for acute ischemic stroke, yet its clinical utility is constrained by a short half-life, continuous infusion requirements, and susceptibility to plasminogen activator inhibitor-1. Tenecteplase, a bioengineered variant of alteplase, was developed to address these limitations through a prolonged half-life, increased fibrin specificity, and enhanced resistance to plasminogen activator inhibitor-1. These structural modifications enable single-bolus administration and reduce systemic fibrinolytic disturbance. In this review, we examine how the targeted molecular modifications of tenecteplase shaped its stepwise translational development in acute ischemic stroke. We first detail the limitations of alteplase, which motivated the transition to alternative agents, the molecular rationale for tenecteplase, and its preclinical evidence. Furthermore, we synthesize the phase II dose-finding trials that established 0.25 mg/kg as providing the optimal efficacy and safety balance, distinguishing it from the excess intracranial hemorrhage observed with the 0.4 mg/kg dose. Finally, we review the pivotal phase III trials across diverse populations demonstrating that tenecteplase 0.25 mg/kg is non-inferior to alteplase and represents a practical, evidence-based alternative, particularly where single-bolus administration may facilitate workflow or transfer for endovascular thrombectomy. Viewed through this molecular-to-clinical framework, the development of tenecteplase illustrates how targeted protein engineering can translate into pharmacological, operational, and clinical advantages in stroke reperfusion therapy.
Introduction
Intravenous thrombolysis remains a cornerstone of reperfusion therapy in acute ischemic stroke, with alteplase serving as the longstanding standard [1,2]. Following its initial approval for acute myocardial infarction (AMI) in 1987, alteplase was approved for acute ischemic stroke in the United States in 1996 and subsequently in Europe, establishing it as the foundational agent for modern intravenous reperfusion therapy [3-6].
Despite its established role, alteplase has several pharmacologic and practical limitations that constrain its optimal use in time-critical emergency settings. These include a short plasma half-life, dependence on continuous infusion, vulnerability to plasminogen activator inhibitor-1 (PAI-1), and relatively modest efficacy in early recanalization of large-vessel occlusion [7-11]. These limitations have stimulated interest in alternative thrombolytic agents with greater fibrin selectivity, more durable pharmacologic activity, and simpler administration [12,13].
Tenecteplase, as a bioengineered variant of alteplase, was developed to address these constraints [14]. Its prolonged half-life, increased fibrin specificity, and enhanced resistance to PAI-1 enable single-bolus administration and reduce systemic fibrinolytic disturbance. Over the past decade, tenecteplase has followed a rigorous translational pathway, from molecular engineering and preclinical validation to dose-finding studies and large-scale randomized trials, evolving into one of the most actively studied thrombolytics in modern stroke care [15-17].
This review examines how the targeted molecular modifications of tenecteplase shaped its translational development in acute ischemic stroke. We trace how this molecular engineering informed preclinical and pharmacological development, stroke-specific dose selection, and the design and interpretation of pivotal clinical trials.
Practical limitations of alteplase in stroke care
In acute ischemic stroke, alteplase is generally administered as a front-loaded regimen of 0.9 mg/kg, with 10% given as a bolus and the remainder infused over 1 hour. Although alteplase remains an established standard for intravenous thrombolysis in acute ischemic stroke, its infusion-based administration introduces practical challenges in real-world stroke care. Because its therapeutic effect depends on uninterrupted delivery after the initial bolus, delays between bolus and infusion are clinically relevant and may reduce effective drug exposure. In a single-center retrospective study including 229 patients, the mean bolus-to-infusion delay was 9±7 minutes [11]. Pharmacologic modeling suggests that such delays may allow substantial declines in circulating drug levels before steady-state exposure is achieved [18]. In addition, compared with tenecteplase, alteplase is less convenient to administer, as its initial bolus is given over 1 minute rather than 5–10 seconds [19]. These issues are particularly relevant in patients undergoing bridging therapy before endovascular thrombectomy. Consistent with these concerns, routine clinical practice data from a 10-hospital network showed that tenecteplase was associated with shorter door-to-needle and door-in-door-out times than alteplase, supporting the practical relevance of avoiding infusion-related workflow constraints [20].
In the setting of endovascular thrombectomy-eligible stroke, the practical limitations of alteplase may be particularly relevant. In the EXTEND-IA TNK (Extending the time for Thrombolysis in Emergency Neurological Deficits-Intra-Arterial using intravenous Tenecteplase) Part 1 trial, tenecteplase achieved approximately twofold higher early recanalization before thrombectomy than alteplase [21]. Moreover, in a drip-and-ship cohort, early recanalization rates were similar between tenecteplase and alteplase (21.4% vs. 18.3%), but the findings suggested that tenecteplase may still achieve recanalization earlier because it is delivered as a single bolus [22]. Taken together, these findings support the possibility that, even among patients eligible for endovascular thrombectomy, the advantage of tenecteplase may lie not only in its pharmacologic profile but also in its ability to provide immediate full-dose thrombolysis without infusion-related workflow constraints.
Alteplase also appears to induce greater systemic fibrinolytic disturbance than tenecteplase, including more pronounced fibrinogen depletion. Although this does not necessarily imply a large difference in intracranial bleeding risk in every trial, it reinforces the biologic rationale for preferring a more fibrin-selective agent [23].
Structural modifications from alteplase
Alteplase, a second-generation tissue-type plasminogen activator (tPA), is a multidomain serine protease composed of five functional domains: an N-terminal finger domain, an epidermal growth factor (EGF)-like domain, kringle 1, kringle 2, and a C-terminal serine protease domain (Figure 1) [24]. The finger domain is the major fibrin-binding region and helps localize tPA to the thrombus surface, and the EGF-like domain contributes to receptor interactions and hepatic clearance. Kringle 1 is involved in clearance-related interactions and structural modulation of the molecule, kringle 2 stabilizes fibrin-dependent plasminogen activation and contributes to assembly of the fibrin-tPA-plasminogen ternary complex, and the serine protease domain contains the catalytic site responsible for conversion of plasminogen to plasmin [25]. Thus, although the entire molecule participates in fibrinolysis, the key engineering advances in tenecteplase were concentrated in the kringle 1 domain, which contributes to its prolonged half-life, and the serine protease domain, which enhances fibrin specificity.
Structural modifications of tenecteplase and their pharmacologic and practical implications. The figure compares the domain structure of alteplase and tenecteplase, highlighting the three engineered substitutions in tenecteplase (T103N, N117Q, and KHRR296-299AAAA). These modifications are associated with increased fibrin specificity, greater resistance to PAI-1, prolonged plasma half-life, and reduced systemic fibrinolysis. The lower panel also illustrates the difference in stroke dosing and administration, with alteplase requiring bolus plus 60-minute infusion and tenecteplase given as a single bolus. EGF, epidermal growth factor; TNK, tenecteplase; PAI-1, plasminogen activator inhibitor-1.
Similar to alteplase, tenecteplase exerts its thrombolytic effect by binding fibrin and catalyzing the conversion of plasminogen to plasmin, which then degrades the fibrin meshwork of thrombi [23,26]. To retain this fibrinolytic mechanism while improving its pharmacologic properties, tenecteplase was engineered as a genetically modified variant of alteplase through three amino acid substitutions: T103N, N117Q, and replacement of the KHRR sequence at residues 296 to 299 with tetra-alanine residues (Figure 1) [14]. Although the T103N substitution primarily reduces plasma clearance by introducing an additional glycosylation site in kringle 1, it inherently impairs fibrin binding and clot lysis [12,13]. The N117Q substitution overcomes this limitation by removing the native glycosylation site at position 117, thereby restoring fibrin affinity and preserving fibrinolytic activity while also slowing plasma clearance [14]. The KHRR296-299AAAA substitution in the serine protease domain provides the major functional advantages of tenecteplase by markedly increasing fibrin specificity, enhancing fibrinogen conservation, and conferring approximately 80-fold greater resistance to PAI-1 [12]. By modifying clearance-related and catalytic domains, tenecteplase achieves greater thrombus selectivity and a longer plasma half-life [27,28].
Preclinical development and early pharmacological profiling
The preclinical development of tenecteplase established the biologic rationale that later supported its clinical translation in acute ischemic stroke. The key preclinical studies of tenecteplase are summarized in Table 1. Although the number of animal studies is smaller than the eventual clinical literature, the available preclinical work is unusually coherent. Early studies showed that molecular engineering could simultaneously reduce plasma clearance, preserve fibrinolytic activity, increase fibrin specificity, and enhance resistance to PAI-1; subsequently, later stroke models demonstrated favorable thrombolytic performance, acceptable hemorrhagic profiles, and, more recently, potential advantages in brain-cell toxicity and multicenter reproducibility.
Molecular and pharmacologic proof of concept
In a foundational 1994 preclinical study using rabbit models [14], tenecteplase showed markedly slower in vivo clearance than wild-type tPA while retaining near-normal fibrin binding and plasma clot lysis activity. Specifically, plasma clearance of the final tenecteplase construct was approximately 8.4-fold lower than that of wild-type tPA (1.9 vs. 16.1 mL/min/kg). Fifteen minutes after intravenous bolus injection, about 50% of tenecteplase remained in the circulation, compared with only about 1% of wild-type tPA [14]. This study also demonstrated that tenecteplase was substantially more clot-selective than wild-type tPA. The triple mutant exhibited approximately 80-fold greater resistance to PAI-1 and roughly 14-fold enhanced relative fibrin specificity. These findings were critical because they showed that tenecteplase did not merely last longer in the circulation; it also retained effective thrombolytic activity while producing less systemic fibrinolysis.
Arterial recanalization and systemic safety in rabbit thrombosis models
The next major step was to determine whether the molecular advantages of tenecteplase translated into more effective recanalization under arterial thrombosis conditions. A rabbit arterial occlusion study compared bolus tenecteplase with recombinant human tPA [28]. In that study, tenecteplase produced faster and more complete recanalization of occluded arteries than tPA, without increasing systemic plasmin generation or peripheral bleeding. The authors additionally reported that, unlike tPA, tenecteplase did not potentiate collagen-induced platelet aggregation in human plasma. These results extended the findings of earlier molecular work by showing that the favorable pharmacokinetics/pharmacodynamics (PK/PD) profile of tenecteplase was not merely a laboratory phenomenon but translated into superior recanalization efficiency in an in vivo arterial model. These findings in the rabbit model are significant for two primary reasons. First, the study showed that bolus tenecteplase could outperform infusion-based tPA in restoring arterial patency, reinforcing the therapeutic relevance of reduced clearance and higher clot selectivity. Second, the absence of excess systemic plasmin generation or peripheral bleeding suggested that tenecteplase might improve thrombolysis without proportionally increasing systemic hemorrhagic liability. In retrospect, these findings anticipated the later clinical argument that the practical advantage of tenecteplase as a single-bolus agent is inseparable from its biologic advantage as a more thrombus-selective fibrinolytic.
Transition to embolic stroke models
The stroke-specific preclinical literature subsequently evaluated whether the pharmacologic advantages of tenecteplase would translate into embolic stroke models. In that setting, tenecteplase achieved recanalization rates comparable to wild-type tPA while producing a numerically lower rate of cerebral hemorrhage, suggesting a more favorable safety profile despite similar thrombolytic efficacy [29]. These observations were later extended in a smallclot embolic stroke model by demonstrating that tenecteplase had a more favorable overall pharmacological profile than alteplase, with implications not only for thrombolysis but also for overall neurological recovery and survival [15]. Taken together, these studies indicated that the favorable properties of tenecteplase were preserved in embolic stroke models, supporting its translational relevance to ischemic stroke.
Recent multicenter preclinical reassessment
After these early rabbit studies, the preclinical literature directly comparing alteplase and tenecteplase remained relatively sparse for many years. A major modern contribution came from a multicenter preclinical comparison of tenecteplase and alteplase in a mouse model of acute ischemic stroke [30]. This work is notable for revisiting tenecteplase within a modern experimental framework, incorporating parallel evaluations at two independent preclinical centers and utilizing both in vivo and in vitro models. According to the report, a single bolus dose of tenecteplase at 2.5 mg/kg achieved infarct reduction similar to that obtained with 10 mg/kg of alteplase, and early tenecteplase administration was associated with fewer hemorrhagic transformations than early alteplase administration, although this advantage was not maintained in the late treatment condition. The study also evaluated toxicity in endothelial cells, astrocytes, and neurons, and reported less neuronal cell death with tenecteplase than with alteplase. Overall, the authors concluded that these two independent preclinical studies supported tenecteplase as a promising reperfusion alternative to alteplase.
These preclinical findings should nevertheless be interpreted in the context of substantial model heterogeneity. The studies used different arterial occlusion and embolic stroke models including variation in clot size and composition, vascular anatomy, treatment timing, and thrombolytic dosing. Moreover, experimental animals generally do not reproduce the advanced age, vascular comorbidities, collateral variability, and extent of blood-brain barrier injury observed in patients with acute ischemic stroke. Thus, favorable recanalization and hemorrhagic profiles in these models provide important mechanistic and translational support but cannot directly predict clinical efficacy or symptomatic intracranial hemorrhage risk.
PK/PD outcome of tenecteplase
Human PK/PD evidence for tenecteplase has evolved in a stepwise translational fashion. The earliest human studies were conducted in AMI, where tenecteplase was first developed and evaluated as a single-bolus fibrinolytic rather than an infusion-based thrombolytic. In that context, early dose-ranging clinical trials established the feasibility of bolus-only delivery [31,32]. Subsequent larger clinical PK/PD analyses in patients with AMI utilized plasma concentration-time data from 179 individuals. Pharmacokinetically, tenecteplase exhibited biphasic disposition, with a dominant early half-life of approximately 17–24 minutes and a terminal half-life of approximately 65–132 minutes. In practical terms, the initial half-life reflects the rapid early decline in plasma concentration immediately after bolus administration, whereas the terminal half-life reflects the slower late-phase elimination of the remaining drug. This biphasic profile helps maintain therapeutically meaningful plasma exposure after a single bolus dose [33]. The stroke-specific PK/PD literature emerged later. The ATTEST (Alteplase-Tenecteplase Trial Evaluation for Stroke Thrombolysis) biomarker substudy demonstrated that in patients with acute ischemic stroke, alteplase 0.9 mg/kg induced broader systemic changes in coagulation and fibrinolysis than tenecteplase 0.25 mg/kg. Specifically, alteplase was associated with significant reductions in plasma fibrinogen, plasminogen, and factor V, as well as prolongation of prothrombin time, whereas tenecteplase caused only minor plasminogen reduction with substantially less fibrinogen and plasminogen consumption. These findings are consistent with clinical expression of the enhanced fibrin specificity conferred largely by the KHRR296-299AAAA substitution, as reflected by less systemic plasminogen activation and fibrinogen consumption in patients with acute ischemic stroke. This supports the concept that tenecteplase is not only pharmacokinetically more convenient but also pharmacodynamically more clot-selective in the stroke setting [34].
Evolution of tenecteplase dosing
Antecedent cardiology experience
Before its formal development in stroke, tenecteplase had already been clinically validated in AMI as a single-bolus thrombolytic. Early thrombolysis in myocardial infarction (TIMI) studies established the feasibility of bolus-only administration and suggested that doses in the 30–50 mg range could achieve effective reperfusion with limited systemic fibrinolytic disturbance [32,35]. In TIMI 10B, the 40 mg dose showed angiographic efficacy essentially equivalent to accelerated alteplase, while the 50 mg dose raised safety concerns, thereby establishing 40 mg as the preferred dose for subsequent cardiology trials [35,36].
This dose was then carried forward into ASSENT-2 (Assessment of the Safety and Efficacy of a New Thrombolytic) trial, in which tenecteplase was administered as a weight-adjusted single bolus of approximately 0.5–0.53 mg/kg and proved therapeutically equivalent to alteplase for 30-day mortality, with similar intracranial hemorrhage but less non-cerebral bleeding (26.4% vs. 28.9%), reinforcing the practical and safety advantages of a bolus-only fibrinolytic strategy [37]. One-year follow-up analysis of the ASSENT-2 trial further strengthened the cardiology case for tenecteplase. At one year, overall mortality remained similar between tenecteplase and alteplase, confirming that the short-term equivalence observed in the original trial was maintained over time [38]. Importantly, this cardiology experience validated tenecteplase as a large-scale, bolus-only fibrinolytic but also showed that the fixed 40-mg or approximately 0.5 mg/kg regimen used in AMI could not be directly extrapolated to acute ischemic stroke, where intracranial bleeding risk and differences in target vascular beds necessitated a more prolonged dose-finding process. This background helps explain why dose exploration became a central issue in stroke development, rather than a simple extension of the AMI program.
Early phase II dose exploration trials in acute ischemic stroke
Early phase II studies of tenecteplase in acute ischemic stroke were primarily designed to determine whether this genetically modified fibrinolytic could be administered safely across a clinically meaningful dose range and whether any particular dose showed a favorable biological or clinical signal. The initial pilot dose-escalation study examined doses from 0.1 to 0.4 mg/kg and found them sufficiently safe for further comparative evaluation [39]. This early work did not identify a single optimal dose, but it established the foundation for subsequent randomized clinical trials by showing that tenecteplase was feasible in the stroke setting and that formal dose selection was both possible and necessary.
Subsequent randomized phase II studies progressively narrowed the field toward 0.25 mg/kg (Table 2). The TNK-S2B (Phase 2B Study of Tenecteplase in Acute Ischemic Stroke) trial compared 0.1, 0.25, and 0.4 mg/kg tenecteplase with alteplase in a seamless phase IIb/III design, and although it was terminated early, it provided an important signal against the 0.4 mg/kg dose because of a higher rate of symptomatic intracranial hemorrhage [40]. A phase IIb TAAIS (Tenecteplase versus Alteplase for Acute Ischemic Stroke) trial in perfusion-selected patients with vessel occlusion then compared 0.1 and 0.25 mg/kg tenecteplase against alteplase and demonstrated superior reperfusion and better clinical outcomes with tenecteplase, helping position 0.25 mg/kg as the leading candidate dose [41]. More recently, TRACE (Tenecteplase Reperfusion therapy in Acute ischemic Cerebrovascular Events), a multicenter phase II trial in China comparing 0.1, 0.25, and 0.32 mg/kg tenecteplase with alteplase, further supported this direction by suggesting that 0.25 mg/kg provided the most encouraging numerical efficacy-safety balance among the tenecteplase doses tested, although no significant between-group differences were observed [42].
Additional phase II studies helped reinforce, rather than redefine, this emerging dose preference. ATTEST evaluated 0.25 mg/kg tenecteplase against alteplase in a broader 4.5-hour thrombolysis population and found similar penumbral salvage, clinical outcomes, and safety, thereby supporting the generalizability of this dose beyond highly selected imaging-based cohorts [43]. Likewise, a smaller supportive study in minor stroke with proven occlusion suggested that 0.25 mg/kg remained feasible and promising in other clinical subgroups [44]. In addition, the phase II TASTE-A (Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance) trial showed that prehospital administration of 0.25 mg/kg tenecteplase while in transit aboard the Melbourne Mobile Stroke Unit was associated with a smaller post-treatment perfusion lesion volume, greater ultra-early clinical recovery, and no excess safety signal compared with alteplase, further supporting the practical and biological validity of this dose in ultra-early stroke care [45]. Although CHABLIS-T (Chinese Acute Tissue-Based Imaging Selection for Lysis in Stroke-Tenecteplase) trial differed in design and focused on a highly selected, perfusion imaging-defined population treated in the extended 4.5–24 hour window, it similarly suggested promise for both 0.25 mg/kg and 0.32 mg/kg without demonstrating a clear advantage of the higher dose [46]. Consequently, these phase II studies did not identify 0.25 mg/kg through a single decisive comparison; rather, they produced a process of convergence in which 0.1 mg/kg appeared less compelling, 0.4 mg/kg lacked a convincing advantage, and 0.25 mg/kg emerged as the most balanced dose to carry forward into later confirmatory trials [47].
Convergence on 0.25 mg/kg: transitional phase II and III trials
Following early dose-exploration studies, the next critical step in tenecteplase development was not simply to confirm efficacy, but to determine which dose should be carried forward into later-phase trials and clinical practice. Among the studies that shaped this transition, EXTEND-IA TNK Part 1, EXTEND-IA TNK Part 2, Norwegian Tenecteplase Stroke Trial (NOR-TEST), and NOR-TEST 2A were particularly influential (Table 3). Overall, these trials helped establish 0.25 mg/kg as the preferred dose by demonstrating its efficacy, the absence of additional benefit with escalation to 0.4 mg/kg, and safety concerns with the higher dose, particularly in older patients [48].
Transitional phase II-III trials that established 0.25 mg/kg as the preferred tenecteplase dose in acute ischemic stroke
EXTEND-IA TNK Part 1 provided the first strong randomized evidence supporting tenecteplase 0.25 mg/kg in patients with large-vessel occlusion undergoing endovascular thrombectomy. 21 In this phase II trial, tenecteplase was compared directly with standard-dose alteplase and was associated with a higher rate of reperfusion before endovascular thrombectomy as well as better functional outcome at 90 days. Although the trial population was highly selected, particularly through vessel imaging and thrombectomy eligibility, the study established that 0.25 mg/kg was an active and clinically meaningful dose in a setting where rapid early reperfusion is especially relevant. EXTEND-IA TNK Part 2 then addressed a more focused question: whether increasing the tenecteplase dose from 0.25 mg/kg to 0.4 mg/kg could further improve reperfusion before endovascular thrombectomy. The answer was essentially no. In this phase II dose-comparison trial, the higher dose did not improve the proportion of patients achieving substantial reperfusion before endovascular thrombectomy [49]. This finding was highly important for dose selection, because it showed that simple dose escalation did not translate into greater efficacy in a biologically favorable population. In other words, 0.25 mg/kg appeared sufficient, whereas 0.4 mg/kg failed to demonstrate added value [48].
The role of NOR-TEST and NOR-TEST 2A in dose selection was somewhat different. Rather than supporting 0.25 mg/kg directly, these trials helped define what should not be taken forward. NOR-TEST, the first phase III trial comparing tenecteplase 0.4 mg/kg with alteplase, failed to demonstrate the prespecified superiority hypothesis, although efficacy and safety outcomes were generally comparable between the two groups; however, interpretation was limited by the large proportion of patients with mild stroke [50]. As a result, NOR-TEST did not convincingly validate 0.4 mg/kg as the optimal dose for broad stroke practice. That uncertainty became much more clinically consequential with NOR-TEST 2A, another phase III trial that enrolled patients with moderate-to-severe acute ischemic stroke. In contrast to the relatively neutral signal from NOR-TEST, NOR-TEST 2A was stopped early and showed worse outcomes with tenecteplase 0.4 mg/kg than with alteplase, including excess symptomatic or any intracranial hemorrhage and poorer functional outcome [51]. These data substantially weakened the case for the higher dose and shifted the field away from 0.4 mg/kg [52].
The harm observed with tenecteplase 0.4 mg/kg may reflect a dose-dependent narrowing of its therapeutic margin. At higher exposure, the molecular advantage of fibrin specificity may be insufficient to prevent off-target fibrinolysis and bleeding from ischemia-injured cerebral microvasculature. Although this mechanism remains inferential, it may explain why dose escalation increased hemorrhagic risk without improving reperfusion.
Therefore, the emergence of 0.25 mg/kg as the preferred tenecteplase dose was driven not only by efficacy, but also by the absence of benefit with dose escalation and the growing evidence of harm at 0.4 mg/kg. This sequence of evidence strongly influenced the design of subsequent phase III trials, most of which adopted 0.25 mg/kg as the dose to be tested against alteplase in routine acute ischemic stroke care.
Non-inferiority of tenecteplase in phase III trials
Recent phase III trials have substantially strengthened the evidence base for tenecteplase as an alternative to alteplase for acute ischemic stroke within 4.5 hours of onset (Table 4) [53]. Across Alteplase Compared with Tenecteplase (AcT), TRACE-2, ATTEST-2, ORIGINAL (Optimal Reperfusion Strategy in Acute Ischemic Stroke with Low-Dose Tenecteplase), and TASTE (Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation), tenecteplase at 0.25 mg/kg consistently met non-inferiority criteria against standard-dose alteplase (although TASTE achieved non-inferiority only in the per-protocol analysis), while major safety outcomes such as symptomatic intracranial hemorrhage and mortality were generally similar between groups. This similarity in intracranial bleeding risk, despite the greater fibrin specificity and reduced systemic fibrinolytic effects of tenecteplase, highlights that symptomatic intracranial hemorrhage is influenced by factors beyond systemic fibrinolysis. These include infarct extent, blood-brain barrier disruption, reperfusion injury, treatment timing, blood pressure, and concomitant endovascular thrombectomy [54]. Thus, the pharmacodynamic selectivity of tenecteplase may reduce systemic fibrinolytic disturbance without consistently lowering symptomatic intracranial hemorrhage across clinical settings.
Characteristics and outcomes of phase III non-inferiority trials comparing tenecteplase 0.25 mg/kg with alteplase in acute ischemic stroke
Trial-specific characteristics and outcomes
AcT trial was the first large pragmatic phase III study to show that tenecteplase could be used in broad real-world practice. It enrolled 1,600 patients in Canada, of whom 1,577 were included in the intention-to-treat population, and found that excellent functional outcome (modified Rankin Scale [mRS] 0–1) occurred in 36.9% of the tenecteplase group and 34.8% of the alteplase group, meeting the prespecified non-inferiority margin, with similar safety outcomes [55]. Its major strength was external validity: it reflected routine stroke thrombolysis practice in a broadly eligible population rather than a highly selected cohort with restrictive inclusion criteria [56]. TRACE-2 trial extended this evidence to a large Chinese population. In patients who were intravenous thrombolysis-eligible but ineligible for endovascular thrombectomy, tenecteplase remained non-inferior to alteplase, with 62% vs. 58% achieving mRS 0–1 at 90 days and comparable symptomatic intracranial hemorrhage rates of about 2% in both groups [57]. ATTEST-2 trial was methodologically notable because it used the full 90-day mRS distribution as the primary endpoint rather than a dichotomized threshold. Tenecteplase was non-inferior to alteplase with an odds ratio of 1.07 (95% CI 0.90–1.27), but superiority was not established [58]. ORIGINAL trial provided another Chinese phase III confirmation. In this trial, 72.7% of tenecteplase-treated patients and 70.3% of alteplase-treated patients achieved the primary endpoint, and non-inferiority was met with similar symptomatic intracranial hemorrhage rates (1.2% vs. 1.2%). The absolute outcome rates were much better than in AcT trial, likely reflecting lower baseline severity and a somewhat different enrolled population [59]. TASTE trial is the key counterbalance in this literature. Unlike the broader pragmatic trials, TASTE trial enrolled patients with salvageable tissue demonstrated on perfusion imaging, making it the most imaging-enriched phase III tenecteplase trial in the early time window. In the intention-to-treat population, tenecteplase did not meet the prespecified non-inferiority threshold for no disability at 90 days, although the per-protocol analysis supported non-inferiority and safety outcomes were similar [60]. Thus, the TASTE trial suggests that the non-inferiority of tenecteplase to alteplase may not uniformly generalize to all specific imaging-selected subgroups.
Robustness of phase III evidence
The strength of the recent evidence base lies in its reproducibility. Tenecteplase has not been supported by a single isolated positive study, but by multiple phase III randomized comparisons across distinct populations [61]. This consistency has shifted the clinical discussion away from whether tenecteplase is a credible alteplase alternative and toward identifying the patient groups and workflows in which it may be preferable. At present, the totality of evidence supports tenecteplase 0.25 mg/kg as a practical and evidence-based non-inferior alternative to alteplase for intravenous thrombolysis in acute ischemic stroke [62]. This accumulated phase III evidence culminated in the U.S. Food and Drug Administration approval of tenecteplase for the treatment of acute ischemic stroke in adults in March 2025. On this basis, guideline recommendations that historically centered on alteplase for intravenous thrombolysis within 4.5 hours of symptom onset have increasingly been extended to include tenecteplase 0.25 mg/kg as an accepted alternative [2,63-65].
Current recommendations differ primarily in whether tenecteplase is preferred for patients proceeding to thrombectomy. The American Heart Association/American Stroke Association guideline and the Canadian Stroke Best Practice Recommendations consider tenecteplase 0.25 mg/kg and alteplase 0.9 mg/kg acceptable options for eligible patients within 4.5 hours, without specifically preferring tenecteplase in thrombectomy candidates [2,64]. In contrast, the European Stroke Organisation recommends tenecteplase 0.25 mg/kg over alteplase in patients with large-vessel occlusion proceeding to thrombectomy, while recognizing it as an alternative in the broader thrombolysis-eligible population [63]. The Korean Stroke Society scientific statement similarly supports tenecteplase as an alternative to alteplase in general and considers it probably superior in thrombectomy-eligible large-vessel occlusion [65].
Accumulated randomized evidence and study-level meta-analyses have largely established tenecteplase 0.25 mg/kg as a clinically effective alternative, and its implementation has already occurred across many stroke systems. The more relevant contemporary questions are therefore how reperfusion outcomes can be improved beyond those achieved with tenecteplase through alternative or adjunctive lytic strategies, and whether treatment effects vary across clinical contexts [66-70]. These contexts include imaging-based selection, endovascular thrombectomy availability and candidacy, occlusion location, stroke severity, treatment window, and workflow demands. Future investigations should focus on these sources of treatment-effect heterogeneity and on strategies that further improve early reperfusion without increasing hemorrhagic risk.
Extended-window tenecteplase thrombolysis
Randomized evidence for intravenous tenecteplase between 4.5 and 24 hours after stroke onset has yielded heterogeneous findings, suggesting that treatment effects depend on imaging selection, occlusion pattern, and access to endovascular thrombectomy (Table 5) [71]. Early imaging-selected studies, including ROSE-TNK (MRI-guided thrOmbolysis for Stroke bEyond Time Window by Tenecteplase) and CHABLIS-T II trials, supported the feasibility and biological activity of late-window tenecteplase but did not establish definitive functional benefit [72,73]. ROSE-TNK trial used diffusion-weighted imaging-fluid-attenuated inversion recovery mismatch, whereas CHABLIS-T II trial enrolled patients with large- or medium-vessel occlusion and a favorable perfusion profile and used an imaging-based reperfusion outcome.
Characteristics and outcomes of randomized trials of intravenous tenecteplase in the extended time window
More favorable clinical results emerged when thrombectomy was unavailable or not indicated. TRACE-III trial improved functional outcomes in perfusion-selected patients with anterior-circulation large-vessel occlusion who lacked access to thrombectomy [74]. OPTION (Tenecteplase for Acute Non-Large Vessel Occlusion 4.5 to 24 Hours After Ischemic Stroke) trial similarly demonstrated benefit in patients with salvageable tissue but without thrombectomy-eligible large-vessel occlusion, although symptomatic intracranial hemorrhage was increased [75].
By contrast, TIMELESS (Thrombolysis in Imaging-Eligible, Late-Window Patients to Assess the Efficacy and Safety of Tenecteplase) and TNK-PLUS (Endovascular Treatment With or Without Preceding Intravenous Tenecteplase in Patients With Late-Window Acute Ischemic Stroke Due to Middle Cerebral Artery Occlusion) trials did not demonstrate additional functional benefit when thrombectomy was readily available and performed in most or all patients [76,77]. Collectively, these findings suggest that late-window tenecteplase has the greatest potential when viable tissue is demonstrated and no timely endovascular reperfusion option is available, whereas its incremental value appears limited when thrombectomy can be performed promptly.
Conclusions
The development of tenecteplase in acute ischemic stroke represents a successful translation from molecular engineering to clinical stroke care. Its prolonged half-life, increased fibrin specificity, and greater resistance to PAI-1 addressed several of the core pharmacologic limitations of alteplase and enabled single-bolus administration.
Building on these molecular and pharmacologic properties, the subsequent clinical development of tenecteplase required careful identification of a stroke-specific dose that preserved efficacy while maintaining an acceptable safety margin. The identification of 0.25 mg/kg as the preferred dose was therefore a critical step in translating the pharmacologic advantages of tenecteplase into clinical stroke therapy.
With this dose established, subsequent large randomized trials across multiple countries and study-level meta-analyses provide consistent evidence that tenecteplase 0.25 mg/kg is non-inferior to alteplase for acute ischemic stroke. Accordingly, tenecteplase should currently be regarded as a practical, evidence-based alternative to alteplase rather than as a universally adopted replacement. Its single-bolus administration offers particular practical advantages in workflow-limited and thrombectomy-eligible settings.
Although tenecteplase has improved molecular and pharmacologic properties compared with alteplase, clinical trials have established non-inferiority rather than superiority. This apparent gap between pharmacologic advantages and clinical outcomes highlights the need for further investigation to identify the specific patient populations and clinical settings in which the molecular and pharmacologic advantages of tenecteplase may translate into meaningful benefits over alteplase.
Future research should focus on alternative or adjunctive lytic strategies that improve upon tenecteplase and on defining how treatment effects vary according to imaging selection, thrombectomy access, occlusion pattern, and workflow context.
Notes
Funding statement
None
Conflicts of interest
The authors have no financial conflicts of interest.
Author contribution
Conceptualization: Jae Wook Jung, Jin Soo Lee. Study design: Jae Wook Jung, Jin Soo Lee. Methodology: Jae Wook Jung, Jin Soo Lee. Data collection: Jae Wook Jung, Jin Soo Lee. Writing—original draft: Jae Wook Jung, Jin Soo Lee. Writing—review & editing: Jae Wook Jung, Jin Soo Lee. Approval of final manuscript: Jae Wook Jung, Jin Soo Lee.
Acknowledgments
We thank the Medical Illustration & Design team at the Medical Research Support Services of Yonsei University College of Medicine for their excellent medical illustrations.
